Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


Abbott is a global, diversified healthcare company devoted to the discovery, development, manufacture and marketing  of pharmaceuticals, nutritional products for children and adults, and medical products, including devices, diagnostic tests and instruments. The company employs approximately 91.000 and markets its products worldwide.


Almac partners with the biopharmaceutical industry to provide biomarker discovery and development solutions ranging from pre-clinical biomarker discovery, through to full companion diagnostic development, biomarker clinical trial management and clinical test delivery from our CLIA lab. We have a portfolio of proprietary discovery arrays and extensive expertise working with formalin fixed paraffin embedded (FFPE) tissue. We utilise this expertise, experience and innovative technology developing diagnostics for our partners and in the development of our own pipeline of molecular diagnostics.

Altos Solutions, Inc.

Altos Solutions, Inc. provides web-based oncology and urology Electronic Medical Records, Practice Management with Integrated Billing, and Patient and Provider Portals. OncoEMR™, UrologEMR™, OncoBilling™, and SeeYourChart™ are unique to oncology and urology practice requirements—from the solo practitioner to 100+ physician practices to hospital centres including community-based, hospital affiliate, or hospital-based practices. Altos is headquartered in Los Altos, California, USA.



Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.


ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialisation of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer.


Astellas Pharma Europe

Astellas is already a proven player in the fields of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. We are now bringing this expertise to bear in the field of oncology. Already we have no fewer than 12 separate therapies under clinical development. Through these programmes, we aim to fulfil not just our potential, but our promise to change tomorrow for patients suffering with conditions such as prostate cancer, other solid tumours such as pancreatic and breast cancer, advanced renal cell carcinoma and haematological malignancies.

Baxter Deutschland GmbH

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. www.baxter.com

Bayer HealthCare

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer. www.bayerhealthcare.com

BN ImmunoTherapeutics

BN ImmunoTherapeutics is vaccine-focused biotechnology company developing and manufacturing novel therapeutic cancer vaccines for the treatment of oncology indications like breast, lung and prostate cancer. The company's lead programme is PROSTVAC-VF, a therapeutic cancer vaccine candidate for advanced prostate cancer, currently being evaluated in a pivotal global Phase 3 programme. PROSTVAC-VF is being developed under a collaboration agreement with the NCI.

Boehringer Ingelheim GmbH

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies, operating globally with 145 affiliates and more than 44,000 employees. Two compounds from the company´s comprehensive oncology research programme, afatinib and nintedanib, are in late-stage clinical development in various solid tumours. For more information please visit: www.boehringer-ingelheim.com

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com

Caris Life Sciences

Caris Life Sciences, a leading biosciences company, provides the world’s foremost evidence-based molecular profiling service, Caris Target Now. Our service, for solid tumours, matches each patient’s biomarker test results, with drug associations described in the clinical literature.  Our informative reports are intended to help the clinician decide which therapies may be effective or ineffective, for each individual patient.  www.carislifesciences.eu.

Cato Software Solutions GmbH

Cato Software Solutions is an internationally active software development company. Its main product cato® supports physicians, pharmacists, and nurses in planning, validating, compounding and administering chemotherapies and other patient-individual medications. cato® is used by app 160 customers in Europe and the US. The newly developed software catoPAN® offers a comprehensive solution for parenteral nutrition covering prescription, batching, and compounding.


Celgene Corporation is an integrated global biopharmaceutical company committed to improving the lives of patients worldwide. Our mission is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions.  www.celgene.com

Celltrion Healthcare Co., Ltd.

Celltrion, Inc. is a biopharmaceutical company specialising in the development of “biosimilars” for monoclonal antibody drugs. Celltrion Healthcare is responsible for the marketing and sales of Celltrion, Inc.’s products and has established a strong global distribution network in preparation for the launch of Celltrion’s antibody biological therapeutics in more than 120 countries. www.celltrionhealthcare.com


CROMSOURCE is an established provider of outsourced clinical research services to the biopharmaceutical and medical device industries. CROMSOURCE supports the full spectrum of clinical development in oncology, from first-in-human conducted in our exceptional early phase unit, through all subsequent phases of pre and post-approval research. CROMSOURCE also offers its outstanding Feasibility Plus service free and without obligation to potential clients." www.cromsource.com

Daiichi Sankyo Europe

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products. While maintaining its portfolio of marketed pharmaceuticals, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology products. Currently, Daiichi Sankyo is testing several potential products to find innovative treatments for different types of cancer.

Delcath Systems, Inc.

Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products. While maintaining its portfolio of marketed pharmaceuticals, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology products. Currently, Daiichi Sankyo is testing several potential products to find innovative treatments for different types of cancer.

Dendreon Corporation

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialisation of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.

Effe Emme S.p.A.

We have been producing single use set for more than 30 years. Our company structure, always evolving, allows us to promptly react to the increasing requirements of the market. Our customers have confidence in us as a reliable partner with a track record of long lasting cooperation. On time delivery and service are our standard.

Eisai Europe Limited

Eisai is one of the world’s leading R&D-based pharmaceutical companies and has defined its corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call human health care (hhc). Eisai recently expanded their UK Hatfield facility which now supports the company’s growing European, Middle Eastern and African (EMEA) business.

Elekta Ltd

Elekta is a total solutions provider of advanced technology needed to run a state-of-the-art cancer centre. A world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy, Elekta supports radiation oncologists and neurosurgeons to aggressively treat tumours and functional targets with high precision while sparing healthy tissue. MOSAIQ®, Elekta’s Integrated Oncology Information Management system for Radiation Oncology and Medical Oncology provides state of the art tools to manage patient data, images and support diverse treatments across the spectrum of cancer care in a single system. www.elekta.com


Focusing our efforts exclusively on cabozantinib (XL184), our most advanced solely-owned product candidate maximising the therapeutic and commercial potential of this compound. We believe cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. We have also established a portfolio of other novel compounds that we believe have the potential to address serious unmet medical needs.

F.Hoffmann-La Roche Ltd

Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is the world’s leading provider of cancer medicines. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

Fresenius Kabi

Fresenius Kabi is dedicated to the therapy and care of critically and chronically ill patients in and outside the hospital. The company offers a broad range of intravenously administered drugs. For cancer treatment, we offer an extensive range of generic drug products. Moreover, the company’s core product range comprises infusion solutions, blood volume substitutes, clinical nutrition, and related medical devices. www.fresenius-kabi.com

GE Healthcare

Healthymagination is GE’s $6 billion commitment to bring high-quality health care at lower cost to more people around the world through our advanced technologies, and research and development capabilities. Just as ecomagination applies our scale and innovation toward tackling environmental challenges, healthymagination offers dramatic new investments toward achieving sustainable health. For more information about GE Healthcare, visit our website at www.gehealthcare.com

Genomic Health

Genomic Health is a molecular diagnostics company focused on the global development and commercialisation of genomic-based clinical laboratory services that analyse the underlying biology of cancer allowing physicians and patients to make individualised treatment decisions.  More than 10,000 physicians in over 65 countries have ordered more than 250,000 Oncotype DX® tests for breast and colon cancer patients.

GlaxoSmithKline Oncology

GSK Oncology is dedicated to the patients, physicians and communities pursuing the fight against cancer. At GSK Oncology, what defines us is our pledge to engage and work in concert with our communities. At GSK Oncology, our portfolio of medicines represents a heritage spanning more than five decades. Whether you are a physician, researcher, or patient, we aspire to know how GSK Oncology might engage with you in fighting the global pandemic known as cancer.
For information on currently approved FDA cancer therapies, please visit the GSK Booth # Y100. For information on our clinical research programmes that our currently recruiting, please visit booth # Y101.

Helsinn Healthcare SA

Headquartered in Switzerland, Helsinn is a dynamic, international, pharmaceutical group with subsidiaries in Ireland and the US. Its business model is focused on in-licensing developing, manufacturing, out-licensing innovative pharmaceutical products, medical devices, nutritional supplement products in oncology and cancer supportive care. Helsinn offers its partners worldwide a full range of services. www.helsinn.com


Hospira is the world’s leading provider of injectable generic drugs and infusion technologies. Through its broad integrated portfolio, Hospira is uniquely positioned to improve patient and caregiver safety whilst reducing healthcare costs.  Hospira offers a broad range of generic acute-care and oncology injectables, biosimilar medicines and integrated infusion therapy and medication management solutions.  The head office for Hospira in Europe, Middle East and Africa is in Royal Leamington Spa, UK. Learn more about Hospira at www.hospira.com.


Imedex is dedicated to improving patient care through the education of medical professionals.  We develop high quality scientific activities that translate the latest research into clinically relevant information. Our established relationships with leading investigators and researchers and some of the world’s most prestigious societies make our educational offerings the most effective in the industry.  We believe that education is the best medicine ®.


Ipsen is a global speciality-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in speciality healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Ipsos Healthcare

Ipsos Healthcare is a leading market research company, dedicated to understanding the motivations, interactions and influences of the multiple stakeholders who impact commercial success in the healthcare industry.


The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

KPS Molecular Diagnostics Centre

KPS is a molecular oncology information company which helps oncologists to turn multiplex molecular diagnostic profile analysis into clinically useful information. Testing is performed in FFPE samples. Integrated databases are developed to quickly find the biological and pharmacological relevance of the identified mutation, and the right targeted drugs on the market or in clinical trials


Labceutics is focused on Enhancing the Value of Laboratory Services for Personalised Medicine. Partnering with Laboratories worldwide, Labceutics provides Pharmaceutical and Diagnostic industries with a “one stop” Personalised Medicine Laboratory service for the development and implementation of Companion Laboratory Testing. Labceutics provides high value testing and related services enabling a high return on investment for Personalised Therapies and Diagnostic. www.labceutics.com

Lilly Oncology

For more than four decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the care of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Our quest is to develop a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care. To learn more about Lilly Oncology’s commitment to cancer, please visit www.LillyOncology.com

MEDIAN Technologies

MEDIAN Technologies provides advanced medical imaging products and services for diagnosing and monitoring cancer patients in clinical trials and routine clinical practice. MEDIAN is changing the paradigm for image interpretation and management by standardising the tools used to analyse image data and automating internal processes wherever possible.  Our goal is to transform image interpretation from a subjective art to a quantitative science to facilitate better, more reliable outcomes for cancer patients.

Medscape Oncology

Medscape Oncology is a comprehensive online resource for clinicians focused on key areas such as breast, lung, prostate, and colorectal cancer, haematologic malignancies, and more.  Oncologists and haematologists will find the latest in-depth news, continuing medical education, and clinical reference tools in these areas, as well as physician commentary on important topics impacting the speciality. www.oncology.medscape.com

Merck Serono

Merck Serono, a division of Merck KGaA, focuses its oncology research on the development of novel therapies that target the tumour cell directly, the tumour environment or the immune system, including the monoclonal antibody Erbitux® which specifically blocks the epidermal growth factor receptor (EGFR), and the development compounds Stimuvax® (cancer immunotherapy) and cilengitide (integrin inhibitor).


Today's MSD is working to help the world be well.  Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information visit www.merck.com

Myriad Genetics GmbH

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialisation of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

NanoString Technologies

NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification, and a cost-effective way to profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously.

Nordic Pharma

The Nordic Group (www.nordicpharmagroup.com) is a rapidly-expanding, pan-European pharmaceutical company with a focus on hospital and orphan products. Teysuno® (TS-1 in Asia) was developed by Taiho Pharmaceutical Company Ltd. and has been authorised in Japan for the treatment of advanced gastric cancer since 1999. Teysuno® is marketed by the Nordic Group in Europe and is already available in Austria, Denmark, Finland, Germany, Norway, Sweden and the UK.

Novartis Oncology

Novartis Oncology discovers and develops innovative therapies, including Glivec® (imatinib), Tasigna® (nilotinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide acetate for injectable suspension) and Exjade® (deferasirox). Novartis has one of the broadest and most comprehensive oncology pipelines in the industry.

Panagene Inc.

PANAGENE is PNA based molecular diagnostic company and has developed real time PCR based PNAClamp™ Technology to detect somatic mutations in EGFR, BRAF, KRAS, and PIK3CA. PANAGENE's PNAClamp™ provides fast, sensitive (<1%) and inexpensive alternative in the mutation detection. We also offer PNA based kits for HPV and TB/NTM.

Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.
For more information please visit www.pfizer.com

Pharmadab d.o.o.

Pharmadab, was established in 2002, as  a Pharmaceutical Engineering Company. Pharmadab is an innovative pharmaceutical company that produces medical devices in field of oncological supportive care, developed on it's own research. Our pharmaceutical products are sold in pharmacies and other specialised shops throughout Europe and world.


PharmaMar's mission is to advance cancer care through the discovery, development and commercialisation of innovative marine-derived medicines. PharmaMar is a Spanish member of Grupo Zeltia, a leader in the development of antitumour drugs of marine origin. Its first product on the market, Yondelis® is the first Spanish antitumoural developed by a company that receives approval from the EMA.


PharmaNet/i3, the inVentiv Health clinical segment, is a leading provider of global product development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialised Phase I-IV product development, bioanalytical, staffing and functional services. For intelligent solutions, PharmaNet/i3 works for you. www.pharmanet-i3.com

Pierre Fabre Medicament

Pierre Fabre Médicament is a French pharmaceutical company represented in more than 140 countries worldwide. Our main anticancer treatments come from Pierre Fabre Research: Navelbine® (vinorelbine), with both IV and oral forms, for advanced breast cancer and non-small cell lung cancer, and more recently Javlor® (vinflunine), for advanced TCCU.

prIME Oncology

prIME Oncology is a global, accredited, professional Independent Medical Education provider specialising in the development and implementation of innovative and clinically relevant educational activities for oncology healthcare professionals. For more information or to inquire about educational opportunities with prIME Oncology, please visit www.prIMEoncology.org

PRMA Consulting

PRMA Consulting are specialists in market access, with a strong focus on oncology. We have extensive experience across a range of tumour types and in-depth understanding of the challenges that manufacturers face in demonstrating product differentiation and value for money to payors of different archetype, enabling us to develop innovative and strategic solutions to any market access problem.


QIAGEN is the leading global provider of Sample & Assay Technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics, Applied Testing, Pharma and Academia. www.qiagen.com


Sandoz, the generics division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz is the pioneer and world leader in developing, manufacturing and commercializing biosimilars and was the first company to launch a biosimilar – Omnitrope (somatropin) – globally. Sandoz’s products – Omnitrope, Binocrit (epoetin alfa), and Zarzio (filgrastim) – are the leading biosimilars in their respective categories.  Sandoz is proud to be increasing patient access to these important therapies by providing high quality, cost effective biopharmaceuticals.

Sanofi Oncology

Sanofi Oncology is dedicated to translating science into effective therapeutics to address unmet medical needs for cancer and organ transplant patients. We employ innovative approaches to drug discovery and clinical development, with the ultimate goal of bringing the right medicines to the right patients.  Our portfolio includes 10 marketed products and 15 investigational compounds in clinical development. www.sanofi.com.

Serono Symposia International Foundation (SSIF)

Serono Symposia International Foundation is an independent, non-profit organisation dedicated to the Continuing Medical Education (CME) of scientists, physicians, nurses, pharmacists and other healthcare professionals through state-of-the-art clinical and scientific activities designed to enhance patient care and improve healthcare outcomes.


Sigma-Tau is a leading, all Italian capital, International pharmaceutical Group, with annual revenues of  € 663 million in 2011 and about 2400 employees worldwide. Out of approximately 25 R&D projects in the pipeline, more than 70 percent are focused on the following therapeutic areas: Rare and Neglected Diseases, Oncology, Immuno-oncology, and Biotechnology. Sigma-Tau has operating subsidiaries throughout Europe, US and Asia and maintains a presence in all of the world’s major pharmaceutical markets.

Sintesi Research

Sintesi Research is a CRO headquartered in Milan, with regional offices in Valencia (Spain), Los Angeles (USA), Buenos Aires (Argentina), Santiago (Chile) and international strategic partnerships, offering full support in planning, managing and evaluating Phase I-IV Clinical Trials. For further information please visit our website www.sintesiresearch.com

Sirtex Medical Europe GmbH

Our innovative technology, SIR-Spheres® microspheres, was approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark. SIR-Spheres microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at more than 60 European institutions. ® SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

Source BioScience

Source BioScience are European leaders in DNA sequencing, genomic services, and bioinformatics analyses and offers a comprehensive portfolio of genomic reagents and antibodies. Source BioScience LifeSciences offer a unique Sanger sequencing service; our local facilities in London, Cambridge, Oxford, Nottingham, Dublin and Berlin combined with our Overnight Service mean we have the flexibility to meet your entire DNA sequencing requirements. Our contract research services feature a broad range of microarray, genotyping and gene expression applications on Affymetrix, Agilent, and NimbleGen Fluidigm platforms.

Takeda Pharmaceuticals Europe Ltd

Takeda is a global research-based pharmaceutical company with a commercial presence covering more than 70 countries. Our mission is better health for patients worldwide through leading innovation in medicine. With oncology a key area of focus, our innovation will result in the discovery, development and delivery of high-quality, novel therapeutics focused on addressing patient needs.

Thaio Pharmaceutical Co., Ltd.

Since Taiho developed the world’s 1st oral anticancer agent, we have been continuing R&D in oncology field for about 45 years. Oral Fluoropyrimidine, S-1 (Teysuno®), is widely used in Asia, and received approval in EU. Taiho continues to concentrate all its intellect and passion on the creation of innovative pharmaceuticals.

Teva Europe

Teva is a leading global pharmaceutical company committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative speciality pharmaceuticals and active pharmaceutical ingredients. Teva’s branded business focus on CNS, pain, oncology, respiratory and women’s health therapeutic areas as well as biologics. Teva has a direct presence in about 60 countries and currently employs approximately 46.000 people around the world.

Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian Medical Systems employs over 5,500 people, located at manufacturing sites, sales and support offices worldwide. www.varian.com

Veridex Part of the Johnson & Johnson family of companies

Veridex, is dedicated to providing physicians with high-value in vitro diagnostic oncology products.  Veridex's products may significantly benefit patients through earlier disease detection and may enable personalised strategies to help improve patient management and outcomes. The CellSearch® assay allows enumeration & characterisation of epithelial circulating tumour cells and is approved for IVD by the US F.D.A. Additional information at www.veridex.com

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings